ImmunoPrecise in the Media

July 26th, 2021

Single source provider of full-service therapeutic antibody development

ImmunoPrecise offers a comprehensive suite of solutions to rapidly deliver high-performing therapeutic antibodies.

LifeSci Partners
July 12th, 2021

A Time for Cocktails. Polytope: A Potential Treatment for Covid-19

Dr. Jennifer Bath, an expert in antibody discovery, as well as translational work in infectious disease, explains why leaving a tenured professorship was a price worth paying to become the CEO of ImmunoPrecise Antibodies (IPA).

November 18th, 2020

COVID-19 ranked top challenge among Deloitte Technology Fast 50 winners, with majority in support of government’s response

Deloitte is honoured to announce this year’s winners of the Technology Fast 50, Companies-to-Watch, and Enterprise Fast 15 awards.

November 9th, 2020

High-quality therapeutic antibody generation for the immuno-oncology sector

Discover the importance of high-throughput and robust methodologies for finding ‘needle-in-the-haystack’ therapeutic antibodies

Equity Guru
November 3rd, 2020

Immunoprecise Antibodies (IPA.V) links up with the Mila Institute on artificial intelligence initiatives

Immunoprecise Antibodies (IPA.V) and research institute for artificial intelligence and machine learning, Mila Institute, inked a research partnership today, according to a press release.

Fox Business
October 18th, 2020

Antibody cocktail therapies tackle coronavirus mutations: ImmunoPrecise Antibodies CEO

Immunoprecise Antibodies CEO Jennifer Bath provides insight into antibody treatments that protect against the coronavirus as it continues to mutate.

October 9th, 2020

Regeneron Antibody Treatment in Focus After President’s Praises, Pharma Company Seeks Emergency Use Authorization From FDA

After President Trump touted it as a quote “cure” for coronavirus, Regeneron is seeking emergency use authorization for its antibody treatment. For more on the latest coronavirus antibody treatments, we spoke to Doctor Jennifer Bath, expert in antibody based therapeutics and the CEO of ImmunoPrecise.

BNN Bloomberg
October 7th, 2020

The development and effectiveness of COVID-19 antibody treatments

Jennifer Bath, CEO of ImmunoPrecise joins BNN Bloomberg to discuss antibody treatments – something we’re hearing a lot about lately. She also talks about the COVID-19 antibody treatment her business is working on.

Fox and Friends
October 4th, 2020

Dr. Jennifer Bath with an inside look on COVID-19 therapeutics

CEO of immunoPrecise Dr. Jennifer Bath discusses coronavirus treatment, function of the antibody cocktail trump is using on ‘Fox & Friends.’

September 30th, 2020

ImmunoPrecise reveals 39% growth in 1Q revenue, initiates pre-clinical coronavirus vaccine study

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study.

September 28th, 2020

Researchers Look to Create ‘Antibody Cocktail’ for Covid

Jennifer Bath, chief executive officer at Immunoprecise Antibodies Ltd., discusses the company’s potentially groundbreaking Covid-19 antibody treatment on “Bloomberg Technology.”

Smallcap Discoveries
September 26th, 2020

Immunoprecise Antibodies (IPA-TSX.V) Interview with CEO Dr. Jennifer Bath

Smallcap Discoveries interviews Dr. Jennifer Bath CEO of ImmunoPrecise Antibodies (IPA-TSX.V)”

Cantech Letter
September 3rd, 2020

ImmunoPrecise Antibodies gets price target raise from Industrial Alliance

Healthcare name ImmunoPrecise Antibodies (ImmunoPrecise Antibodies Stock Quote, Chart, News TSXV:IPA) is now gaining traction, says Industrial Alliance Securities analyst Chelsea Stellick.”

University of Victoria
August 19th, 2020

Using plant power in the rapid production of COVID-19 antibody tests

To meet the global demand for COVID-19 spike protein needed for antibody test kits, University of Victoria plant biologist Peter Constabel has turned to an unexpected source: a relative of the tobacco plant.

University of Victoria
July 17th, 2020

Mapping the COVID-19 recovery

UVic scientists are leading efforts to protect our health, and working with the community to ensure the social and economic resilience of our society.

May 18th, 2020

ImmunoPrecise Antibodies (IPA) and EVQLV

PolyTope mAb Therapy™, a defined antibody combination designed to target multiple epitopes and mechanisms of viral evasion, and enabled by IPA’s discovery platforms (including B Cell Select™ and DeepDisplay™) and ImmunoPrecise subsid…